Piper Sandler raises Madrigal Pharmaceuticals stock price target to $540
PositiveFinancial Markets

Piper Sandler has raised its price target for Madrigal Pharmaceuticals to $540, reflecting strong confidence in the company's potential. This adjustment is significant as it highlights the optimism surrounding Madrigal's innovative treatments and their impact on the market. Investors and stakeholders should pay attention, as this could indicate a promising future for the company and its shareholders.
— Curated by the World Pulse Now AI Editorial System